Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 2/2014

01.09.2014 | Leitlinien

DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen

9 Internationale Klassifikation für Funktionsfähigkeit, Behinderung und Gesundheit (ICF)

verfasst von: Dr. U. Kiltz, W. Mau, U. Repschläger, E. Böhle, J. Braun

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 2/2014

Einloggen, um Zugang zu erhalten

Auszug

Schlüsselfrage 9: Welche Probleme der Alltagsfähigkeit und soziale Teilhabe sollen erfasst werden (ICF)? …
Literatur
1.
Zurück zum Zitat Rudwaleit M et al (2009) The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60(3):717–727PubMedCrossRef Rudwaleit M et al (2009) The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60(3):717–727PubMedCrossRef
2.
Zurück zum Zitat Heijde DM van der et al (2009) Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 11(4):R124PubMedCrossRefPubMedCentral Heijde DM van der et al (2009) Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 11(4):R124PubMedCrossRefPubMedCentral
3.
Zurück zum Zitat Davis JC Jr et al (2007) Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 57(6):1050–1057PubMedCrossRef Davis JC Jr et al (2007) Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 57(6):1050–1057PubMedCrossRef
4.
Zurück zum Zitat Boonen A et al (2008) Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 35(4):662–667PubMed Boonen A et al (2008) Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 35(4):662–667PubMed
5.
Zurück zum Zitat Kiltz U et al (2012) Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 64(9):1415–1422CrossRef Kiltz U et al (2012) Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 64(9):1415–1422CrossRef
6.
Zurück zum Zitat Boonen A et al (2010) ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis 69(1):102–107PubMedCrossRef Boonen A et al (2010) ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis 69(1):102–107PubMedCrossRef
7.
Zurück zum Zitat Boonen A et al (2009) Aspects relevant for functioning in patients with ankylosing spondylitis according to the health professionals: a Delphi study with the ICF as reference. Rheumatology (Oxford) 48(8):997–1002 Boonen A et al (2009) Aspects relevant for functioning in patients with ankylosing spondylitis according to the health professionals: a Delphi study with the ICF as reference. Rheumatology (Oxford) 48(8):997–1002
8.
Zurück zum Zitat Echteld I van et al (2006) Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol 33(12):2475–2483PubMed Echteld I van et al (2006) Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol 33(12):2475–2483PubMed
9.
Zurück zum Zitat Dagfinrud H et al (2005) Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions. J Rheumatol 32(3):516–523PubMed Dagfinrud H et al (2005) Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions. J Rheumatol 32(3):516–523PubMed
10.
Zurück zum Zitat Ward MM (1999) Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12(4):247–255PubMedCrossRef Ward MM (1999) Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12(4):247–255PubMedCrossRef
11.
Zurück zum Zitat Boonen A et al (2009) Which aspects of functioning are relevant for patients with ankylosing spondylitis: results of focus group interviews. J Rheumatol 36(11):2501–2511PubMedCrossRef Boonen A et al (2009) Which aspects of functioning are relevant for patients with ankylosing spondylitis: results of focus group interviews. J Rheumatol 36(11):2501–2511PubMedCrossRef
12.
Zurück zum Zitat Sigl T et al (2005) ICF based comparison of disease specific instruments measuring physical functional ability in ankylosing spondylitis. Ann Rheum Dis 64(11):1576–1581PubMedCrossRefPubMedCentral Sigl T et al (2005) ICF based comparison of disease specific instruments measuring physical functional ability in ankylosing spondylitis. Ann Rheum Dis 64(11):1576–1581PubMedCrossRefPubMedCentral
13.
Zurück zum Zitat Gordeev VS et al (2010) Role of contextual factors in health-related quality of life in ankylosing spondylitis. Ann Rheum Dis 69(1):108–112PubMedCrossRef Gordeev VS et al (2010) Role of contextual factors in health-related quality of life in ankylosing spondylitis. Ann Rheum Dis 69(1):108–112PubMedCrossRef
14.
Zurück zum Zitat Mau W et al (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32(4):721–728PubMed Mau W et al (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32(4):721–728PubMed
15.
Zurück zum Zitat Zink A, Mau W, Schneider M (2001) Epidemiologische und sozialmedizinische Aspekte entzündlich-rheumatischer Systemerkrankungen. Internist (Berl) 42(2):211–216, 219–222 Zink A, Mau W, Schneider M (2001) Epidemiologische und sozialmedizinische Aspekte entzündlich-rheumatischer Systemerkrankungen. Internist (Berl) 42(2):211–216, 219–222
16.
Zurück zum Zitat Zink A et al (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis – results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27(3):613–622PubMed Zink A et al (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis – results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27(3):613–622PubMed
17.
Zurück zum Zitat Ward MM, Kuzis S (2001) Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 28(2):315–321PubMed Ward MM, Kuzis S (2001) Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 28(2):315–321PubMed
18.
Zurück zum Zitat Ward MM et al (2008) Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum 59(4):497–503PubMedCrossRef Ward MM et al (2008) Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum 59(4):497–503PubMedCrossRef
19.
Zurück zum Zitat Cakar E et al (2009) Work disability in ankylosing spondylitis: differences among working and work-disabled patients. Clin Rheumatol 28(11):1309–1314PubMedCrossRef Cakar E et al (2009) Work disability in ankylosing spondylitis: differences among working and work-disabled patients. Clin Rheumatol 28(11):1309–1314PubMedCrossRef
20.
Zurück zum Zitat Boonen A et al (2002) Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 61(5):429–437PubMedCrossRefPubMedCentral Boonen A et al (2002) Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 61(5):429–437PubMedCrossRefPubMedCentral
21.
Zurück zum Zitat Boonen A et al (2010) Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 69(6):1123–1128PubMedCrossRef Boonen A et al (2010) Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 69(6):1123–1128PubMedCrossRef
22.
Zurück zum Zitat Boonen A et al (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60(4):353–358PubMedCrossRefPubMedCentral Boonen A et al (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60(4):353–358PubMedCrossRefPubMedCentral
23.
Zurück zum Zitat Barkham N et al (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69(11):1926–1928PubMedCrossRef Barkham N et al (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69(11):1926–1928PubMedCrossRef
24.
Zurück zum Zitat Maksymowych WP et al (2010) Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 37(2):385–392PubMedCrossRef Maksymowych WP et al (2010) Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 37(2):385–392PubMedCrossRef
25.
Zurück zum Zitat Keat AC et al (2008) Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology (Oxford) 47(4):481–483 Keat AC et al (2008) Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology (Oxford) 47(4):481–483
26.
Zurück zum Zitat Bönisch A (2005) Evaluation eines Schulungsprogramms für Patienten mit Spondylitis ankylosans. In: Pertermann F (Hrsg) Prädiktion, Verfahrensoptimierung und Kosten in der medizinischen Rehabilitation. Regensburg, S 51–102 Bönisch A (2005) Evaluation eines Schulungsprogramms für Patienten mit Spondylitis ankylosans. In: Pertermann F (Hrsg) Prädiktion, Verfahrensoptimierung und Kosten in der medizinischen Rehabilitation. Regensburg, S 51–102
27.
Zurück zum Zitat Krauth C (2005) Gesundheitsökonomische Evaluation eines Patientenschulungsprogramms Spondylitis ankylosans in der stationären Rehabilitation. In: Pertermann F (Hrsg) Prädiktion, Verfahrensoptimierung und Kosten in der medizinischen Rehabilitation. Regensburg, S 103–143 Krauth C (2005) Gesundheitsökonomische Evaluation eines Patientenschulungsprogramms Spondylitis ankylosans in der stationären Rehabilitation. In: Pertermann F (Hrsg) Prädiktion, Verfahrensoptimierung und Kosten in der medizinischen Rehabilitation. Regensburg, S 103–143
28.
Zurück zum Zitat Mau W, Ehlebracht-Konig I (2013) Rehabilitation in axial spondyloarthritides. Rehabilitation (Stuttg) 52(1):51–62 Mau W, Ehlebracht-Konig I (2013) Rehabilitation in axial spondyloarthritides. Rehabilitation (Stuttg) 52(1):51–62
Metadaten
Titel
DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen
9 Internationale Klassifikation für Funktionsfähigkeit, Behinderung und Gesundheit (ICF)
verfasst von
Dr. U. Kiltz
W. Mau
U. Repschläger
E. Böhle
J. Braun
Publikationsdatum
01.09.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe Sonderheft 2/2014
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-014-1434-8

Weitere Artikel der Sonderheft 2/2014

Zeitschrift für Rheumatologie 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.